FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
Status:
Unknown status
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer
by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin),
prolonged the overall survival, time to progression and improved response rate in metastatic
lung cancer in a large phase III clinical trial in china, so we design this trial to evaluate
the safty and efficacy of FolFox4 plus Endostar in patients with advanced colorectal cancer
Phase:
Phase 2
Details
Lead Sponsor:
Simcere Pharmaceutical Co., Ltd
Collaborator:
The Affiliated Changzhou Tumor Hospital of Suzhou University